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Given the explosion of research on induced pluripotent stem (iPS) cells, it is timely to consider the 
various ethical, legal, and social issues engaged by this fast-moving field. Here, we review issues 
associated with the procurement, basic research, and clinical translation of iPS cells.Since the 2007 announcement that adult 
human skin cells can be reprogrammed 
to act like human embryonic stem cells 
(hESCs) (Takahashi et al., 2007), stem cell 
research has experienced renewed atten-
tion and enthusiasm from scientists, the 
public, patient groups, and policy mak-
ers. These new cells, called induced pluri-
potent stem (iPS) cells have been hailed 
as an ethical victory (Aalto-Setala et al., 
2009) because they represent a way of 
producing valuable hESC-like pluripotent 
stem cells without involving the destruc-
tion of human embryos. The develop-
ment of iPS cells has also opened up 
stem cell research, in part due to the fact 
that the technology is more accessible, 
less expensive, and less resource con-
strained (i.e., does not require the use of 
embryos or scarce human oocytes) than 
that required for hESC research.
The rapid advances in iPS cell research 
and the significant expectations placed 
upon this field make it both timely and 
imperative to consider the ethical, legal, 
and social issues (ELSI) associated with 
it and their impact on the iPS cell policy 
landscape. This was the goal of an interna-1032 Cell 139, December 11, 2009 ©2009 Etional workshop held in association with the 
2009 annual meeting of the International 
Society for Stem Cell Research (http://
www.isscr.org), which brought together 
an international team of stem cell scien-
tists, bioethicists, and ELSI scholars. In 
this article, which emerged from the work-
shop, we consider various ethical, legal, 
social, and policy issues associated with 
aspects of iPS cell procurement and basic 
research including privacy, consent, intel-
lectual property, and potential uses. Next, 
we address features of clinical translation 
including safety, regulation, and oversight. 
Finally, we conclude by reflecting on the 
theme of exceptionalism and the overarch-
ing context of commercial pressure. Our 
intent is not to provide a comprehensive 
analysis of these complex issues or a list 
of recommendations but rather to highlight 
key areas that require both further reflec-
tion and research.
Privacy
One of the most significant issues asso-
ciated with iPS cell procurement and 
research relates to the privacy interests 
of cell donors. As is true in other areas of lsevier Inc.human tissue research, iPS cell lines result 
from a living individual and, as such, carry 
that individual’s DNA “fingerprint,” which 
contains an immeasurable amount of infor-
mation about the donor including genetic 
predisposition to disease. Inappropriate 
disclosure of this information could vio-
late that individual’s privacy and result in 
social, economic, or other risks (Sugarman, 
2008). Related concerns regarding genetic 
privacy have been addressed in consid-
erable depth in the context of genetics 
research (Lowrance and Collins, 2007). The 
Genetic Information Nondiscrimination Act 
of 2008 in the US is an example of a legis-
lative response to some of these concerns 
(http://www.gpo.gov/fdsys/pkg/ PLAW-
110publ233/html/PLAW-110publ233.htm). 
Even if the original cells used to derive iPS 
cells were isolated from a donor who is no 
longer alive (and stored as a clinical sample 
or in a cord blood stem cell bank, for exam-
ple), the iPS cell DNA still contains informa-
tion about close relatives of the donor and 
thereby engages their privacy interests.
One way for researchers to address 
these concerns is to de-identify or anony-
mize the data at the time of donation. How-
ever, there are various problems with this 
approach. First, there are clinical, research, 
and policy reasons why anonymization 
(that is, de-linkage from identifiable infor-
mation) may not be an ideal approach. 
For instance, future clinical applications 
(e.g., transplantation) may necessitate 
obtaining follow-up information about the 
donor’s health status. Second, with the 
advent of large-scale genome-wide asso-
ciation studies, technology now exists 
to detect a specific individual’s single 
nucleotide polymorphism, even when de-
identified and in a pooled data set (http://
grants.nih.gov/grants/gwas/background_
fact_sheet_20080828.pdf). Accordingly, it 
is important for iPS cell researchers to 
remain vigilant in their efforts to protect 
the privacy interests of their subjects by 
taking concrete steps such as structur-
ing their research so as to limit traceable 
cross-references to public databases 
and by using state of the art security 
 measures.
In addition, iPS cell research carries 
the possibility of incidental findings. The 
concern is that, perhaps in the course of 
deriving a cell line, or developing a dis-
ease model, researchers will unintention-
ally discover that the donor suffers from 
some kind of condition or predisposition 
to disease, raising the question of what 
they should do with that information. 
The question of how to deal with inci-
dental findings is a significant research 
ethics issue that impacts many areas 
of biomedical research and is beyond 
the scope of this article. Nonetheless, 
researchers need to be aware of this 
possibility and to prepare for it, espe-
cially when obtaining informed consent.
Consent, and Withdrawal of 
Consent
Consent is crucial whenever humans are 
asked to participate in research, whether 
as research subjects or as donors of 
research materials, including cells and 
tissue. There are numerous consent 
challenges that, while not unique to iPS 
cell research, should be considered. One 
of the most pressing is the nature of the 
consent that is required of a cell donor. 
According to most research ethics 
frameworks, research participants must 
provide voluntary and informed consent 
to participate in research protocols. This 
approach ensures that any assumption of risk by research participants is com-
pletely voluntary and respectful of their 
autonomy. This standard requires that 
participants be informed about the spe-
cific details of the proposed research.
The potential for iPS cell lines to be 
used indefinitely for future research that 
is not yet contemplated may make it chal-
lenging to obtain truly informed consent 
by traditional standards. Similar claims 
have been made in the comparable con-
text of biobanking, where this issue has 
emerged as a contentious topic. Some 
commentators have argued in favor of a 
shift toward a broad or blanket consent 
model where participants consent to a 
wide range of generally defined research 
activities including, possibly, unforeseen 
future uses (Hansson et al., 2006). How-
ever, others stress the importance of 
maintaining rigorous consent standards, 
which requires enumerating specific 
research uses (Mascalzoni et al., 2008).
Will the consent debates associated 
with iPS cell research get caught up in 
this broader debate? The answer may 
be yes, as exemplified by pluripotent 
germline cultures derived from human 
testicular tissue that are unavailable for 
further study because of restrictions in 
the donors’ consent forms (http://www.
nature.com/nature/journal/v460/n7258/
full/460933a.html). Such dilemmas seem 
likely to push the consent issues associ-
ated with iPS cell research to the fore-
ground. The possibility of deriving gam-
etes in vitro from iPS cells makes this 
issue even more acute (Kee et al., 2009). 
Indeed, a specialized approach to con-
sent for iPS cell research has been sug-
gested, where the form notifies donors 
about some common uses and includes 
a request to recontact donors if unan-
ticipated uses emerge (Aalto-Setala et 
al., 2009). The potential for uses of cell 
lines that some donors might find objec-
tionable (e.g., producing human-animal 
chimeras, derivation of human gametes 
and fertilization research, use for basic 
research versus transplantation, etc.) 
arguably also needs to be recognized 
and reflected in the consent process 
(Aalto-Setala et al., 2009).
There are, of course, many other rel-
evant consent issues, including the 
question of whether and to what degree 
surrogate consent is sufficient for partici-
pants without capacity (e.g., can parents Cell 139, Deconsent to the participation of children in 
iPS cell research) and under what circum-
stances is it acceptable to use currently 
stored samples for iPS cell research 
without consent (http://www.isscr.org/ 
guidelines/ISSCRhESCguidelines2006.
pdf; see also the UK’s Human Fertilisa-
tion and Embryology Act 2008, ch. 22, 
Schedule 3).
In addition, traditional research eth-
ics standards require that individu-
als be able to withdraw from research 
and terminate their participation at any 
time. This right to withdraw holds a 
central place in international research 
ethics frameworks (http://www.wma.
net/en/30publications/10policies/b3/
index.html; http://conventions.coe.int/
treaty/en/Treaties/Html/164.htm). How-
ever, with hESC research, exceptions 
to this rule are the norm. Some guide-
lines suggest that donors can withdraw 
their consent only until the creation of 
an anonymized cell line (http://www.
cihr-irsc.gc.ca/e/34460.html), and oth-
ers until an embryo (or blastocyst) 
is used in cell line derivation (http://
www. stemcellnetwork.ca/) or for any 
research project (http://www.isscr.org/
guidelines/ISSCRhESCguidelines2006.
pdf, para. 11.2). However, in other forms 
of tissue research, the right to withdraw 
consent endures, even allowing donors 
to request the destruction of their sam-
ple (http://www.ukbiobank.ac.uk/docs/
Informationleaflet130608.pdf).
Once an iPS cell line has been created, 
can a donor withdraw his or her consent 
to participate in research and, in so 
doing, prohibit further research on that 
cell line? If the answer is yes, the implica-
tions for researchers could be immense. 
In some circumstances, depending on 
how the cell line has been used and in 
which jurisdictions, “it may be impossi-
ble for donors to meaningfully withdraw 
consent for use” (Sugarman, 2008).
Nonetheless, there are also factors 
that suggest a right of withdrawal should 
endure. It may become increasingly 
necessary—particularly as the research 
moves toward clinical use—to recon-
tact cell donors and keep links between 
the cell line and the donor’s on-going 
health status (Aalto-Setala et al., 2009). 
It has been argued that “if linkage and 
recontact is required, the right to with-
draw consent, at some level, should cember 11, 2009 ©2009 Elsevier Inc. 1033
endure” (Caulfield et al., 2007). Balanc-
ing the diverse interests associated with 
iPS cell research, including those of the 
donors and the potential social benefits 
of the research, will be truly challeng-
ing. Clear policy positions should be 
adopted and followed consistently so 
as to avoid unnecessary impediments to 
the research, while ensuring protection 
of individual rights.
Reach-through Rights
Related to consent withdrawal is the 
broader issue of the philosophical and 
legal underpinnings of a donor’s continu-
ing interest in controlling the scientific 
and commercial uses of lines generated 
from his or her cells, and in the nature 
and results of the research conducted 
on them. In other words, what is the 
extent of a donor’s legal interest, if any, in 
resulting cell lines? Should donors have 
the right to receive financial benefit from 
commercial profits resulting from lines 
derived from their cells? Are they able 
to exert any control over the future uses 
of such lines? If they are able to “reach 
through” and exercise such rights, what 
is the basis of that power?
Legal rationales are one of the most 
often cited sources of reach-through 
rights, and yet their application is far from 
straightforward. For instance, the ques-
tion of whether donors retain a property 
interest in their bodily tissues or genetic 
matter after providing it for research pur-
poses has been touched on by a number 
of American courts (e.g., Greenberg et 
al. v. Miami Childrens Hospital Research 
Institute 264 F. Supp. 2d 1064,SD. Fla. 
2003; Washington University v. Cata-
lona, 437 F. Supp. 2nd 985,E.D. Mo. 2006, 
http://www.circare.org/lex/03cv01065_
opinion.pdf; Moore v. The Regents of the 
University of California 51 Cal. 3d. 120, 
793 P.2d. 479, 271 Cal. Rptr. 146, CA. 
1990). In each of these cases, the Court 
rejected the claims of research partici-
pants to property rights on the biologi-
cal materials that they contributed to 
research. The Court in Washington Uni-
versity v. Catalona noted the existence of 
strong public policy arguments against 
allowing research participants to retain 
control over biological samples they 
provide. Nevertheless, confusion and 
uncertainty remain regarding the state of 
the law in this area as no definitive juris-1034 Cell 139, December 11, 2009 ©2009 Eprudence has emerged. And, of course, 
international variation in legislation, juris-
prudence, and philosophical approaches 
add even more complexity to the use of 
property rights in this context.
Autonomy and dignity are also com-
monly used to support donor’s reach-
through rights. Indeed, there are numer-
ous cases where courts have reinforced 
an autonomy-derived right of control 
over tissue and health information (for 
Canadian examples, see R. v. Dyment, 
1988, 2 S.C.R. 417, 429: “such informa-
tion remains in the fundamental sense 
one’s own, for the individual to com-
municate or retain as he or she sees fit,” 
and McInerney v. McDonald, 1992, 2 
S.C.R. 138). Similarly, in research ethics 
policy frameworks, autonomy is usually 
the dominant theme. Will this approach 
withstand careful scrutiny in the realm of 
iPS cell research where the donor’s orig-
inal cells are significantly manipulated, 
transformed, and expanded in different 
ways by researchers? Though the resul-
tant iPS cell line is genetically identical to 
the donor, the cells are arguably trans-
formed into a new and distinct product 
that bears little resemblance to the cells 
originally taken from the donor. Does this 
methodological reality limit the donor’s 
right of control? Alternatively, the resul-
tant cell lines contain the donor’s genetic 
information and the potential for future 
linkage to personal information. In addi-
tion, giving donors more lasting control 
may encourage donation. To what extent 
do these factors mean that the donor 
should maintain a reach-through right of 
control?
Intellectual Property Challenges
Efficient application of intellectual prop-
erty rights can present a major challenge 
to innovation and is expected to play a 
significant role in the progress of iPS cell 
research. It has been speculated that 
hESC patent activity has (or may) impede 
research and development in this area 
(Loring and Campbell, 2006). On the 
other hand, there are also strong argu-
ments in favor of patents and their role in 
innovation. Undoubtedly, more research 
is needed to determine whether the con-
cerns about patents are justified and to 
assess the actual impact of patents on 
research and development (Caulfield et 
al., 2008).lsevier Inc.In the US, controversies about over-
broad claims (which cover the cells and 
the methods to grow them), aggressive 
licensing schemes, and patent challenges 
have been hallmarks of James Thom-
son’s foundational hESC patents. These 
patents have been confirmed and remain 
in force until 2015, but the challenges 
resulted in a clarification of the claims and 
a change in licensing policy. Conversely, 
the European Patent Office recently 
denied a similar claim on moral grounds 
following the European Union’s Directive 
on the legal protection of biotechnologi-
cal inventions, adopted in 1998 (http://
documents.epo.org/projects/babylon/
eponet.nsf/0/428862B3DA9649A9C1257
50E002E8E94/$FILE/G0002_06_en.pdf). 
A clause in the Directive has been inter-
preted to preclude patents on inventions 
that required the destruction of human 
embryos on the grounds that they are 
contrary to ordre public, or “public order.” 
It is instructive to observe the patent land-
scape in the hESC field as the path of iPS 
cell patenting is likely to be influenced by 
these precedents.
Potentially, iPS cell technology may 
face barriers from patent activity, largely 
because of the many approaches used 
to create iPS cells and the limited knowl-
edge of whether and how these cells 
differ from each other and from hESCs. 
On first analysis, the patent applications 
by Shinya Yamanaka (who discovered 
iPS cells and was granted a patent in 
Japan) and other inventors (including 
Bayer’s Kazuhiro Sakurada and the Uni-
versity of Wisconsin’s James Thomson) 
appear extraordinarily broad, encom-
passing all human pluripotent stem 
cells and their derivatives. It is possible 
that patents for hESC derivation meth-
ods may encompass iPS cell derivation 
processes, although the US Patent and 
Trademark Office refused to consider an 
initial attempt to include iPS cells under 
Thomson’s original composition claim. 
As is true for all patent applications, in 
the context of iPS cell-related claims 
patent examiners will need to determine 
whether the discoveries are new, not 
obvious to someone skilled in the art, 
and useful.
Other questions remain. Is each varia-
tion of a reprogramming technique a 
newly patentable process, an unpatent-
able obvious next step, or an activity 
lacking inventiveness? If the process is 
patentable, is the resulting iPS cell a dif-
ferent and patentable product or has the 
inventor merely developed a new way to 
make an already protected iPS cell? If a 
patented technique is applied to a new 
cell type, can the new cell type be pat-
ented independently from the original? 
Different iPS cell lines show different gene 
expression patterns and traits, are more 
or less amenable to differentiation, or are 
more or less efficiently reprogrammed. 
Determining whether any, some, or all of 
these traits satisfy the requirements for 
patenting is crucial to determining which 
iPS cell lines and derivation techniques 
are entitled to patent protection (Vrtovec 
and Scott, 2008).
The patent landscape is important not 
only for efficient research progress but 
also for the commercialization and clinical 
translation of the technology. Patenting 
can impede development of innovative 
technologies when multiple patents held 
by different inventors are necessary to 
move the technology from basic research 
to useful clinical products or processes. 
Because of the uncertainty of a patent’s 
reach, it can be cost prohibitive to iden-
tify those patents that are relevant to the 
work necessary to create the medical 
advances being pursued. The primary 
concern is that if patents proliferate in 
a research area, they will develop into a 
thicket too complicated and expensive 
to negotiate in order to efficiently exploit 
the technology for human benefit (Berg-
man and Graff, 2007). More research is 
necessary to probe the degree to which 
these concerns are supported by rel-
evant evidence.
The Ethical Use of iPS Cells
Despite the fact that iPS cell research 
was initially hailed as a technology that 
would help resolve some of the most 
controversial ethical dilemmas associ-
ated with hESC work, various ethical 
challenges that were first raised with 
early stem cell research remain, includ-
ing concerns about the creation of 
embryos for research and about clon-
ing. Further, these are joined by other 
emerging issues, such as the derivation 
of gametes. Although many of these 
issues were first engaged by hESC 
research, the relevant ease with which 
iPS cell samples can be obtained (ver-sus embryos), the fact that they can 
potentially be taken without knowledge 
or consent, and the general accessibil-
ity of this technology (compared to hESC 
research) mean that issues of use war-
rant particular  consideration.
A crucial part of iPS cell research, 
which is necessary to move the field 
toward clinical uses, is the development 
of animal models to test the function and 
safety of iPS cell therapies. However, 
some animal models raise ethical and 
policy issues that must be considered. 
At the most extreme end, tetraploid com-
plementation may allow human cloning. 
By introducing iPS cells into tetraploid 
blastocysts, one can create an entire 
animal whose genetic makeup is identi-
cal to the somatic cell donor including 
the mitochondria, in contrast to somatic 
cell nuclear transfer (SCNT) methods. 
However, some evidence suggests that 
hESCs and iPS cells may correspond 
more closely to mouse epiblast-derived 
stem cells. These cells are obtained 
from early post-implantation embryos 
rather than from blastocysts and, while 
still pluripotent as judged by in vitro dif-
ferentiation and teratoma formation, are 
unable to contribute to chimeras after 
reintroduction into pre-implantation 
embryos. It is possible that human iPS 
cells will similarly be unable to make 
new embryos. The UK’s governing leg-
islation would permit at least a limited 
test of this theory, but any resulting 
human embryos could not be kept after 
the appearance of the primitive streak or 
beyond 14 days in vitro and could not be 
implanted. Questions remain regarding 
whether iPS cells are really equivalent 
to hESCs, and more research on both 
types of stem cells is required.
Arguably one of the most unique and 
ethically fraught potential uses of iPS cell 
technology is the derivation of gametes. 
Researchers have already claimed to 
have successfully derived sperm from 
mouse cells (Nayernia et al., 2006; see 
also Kee et al., 2009). Although the deri-
vation of gametes using iPS cells may be 
an important research tool, the possibil-
ity that they may be used for reproduc-
tive purposes raises ethical concerns 
including, but not limited to, consent 
issues, safety, concerns about clon-
ing, the potential to surreptitiously have 
a child by an unwilling donor, and the Cell 139, Dpotential right of a child to know his or 
her parents. These issues, among oth-
ers, are starting to receive international 
attention (http://www.hinxtongroup.org/
Consensus_HG08_FINAL.pdf). Despite 
these concerns, iPS cell technology may 
improve assisted reproduction practices 
and assist in advancing our scientific 
understanding of basic development 
and fertility.
Pluripotent stem-cell derived gam-
etes are challenging from a regulatory 
perspective. In vitro-derived gametes, 
whether from hESCs or iPS cells, will 
have to be tested in the laboratory at 
some point for functionality. This testing 
will require the creation and destruction 
of embryos, which of course remains a 
highly contentious topic. Although some 
jurisdictions, including the UK and Sin-
gapore, permit the creation of human 
embryos for research purposes, other 
jurisdictions prohibit the practice. Many 
jurisdictions only permit in vitro devel-
opment of a human embryo for up to 14 
days (Australia, Canada, Estonia, Fin-
land, France, Hungary, Iceland, India, 
Israel, Japan, Slovenia, Singapore, 
South Africa, Spain, Sweden, Switzer-
land, UK) (Isasi and Knoppers, 2006). 
This regulatory patchwork may prevent 
the study of the development of gametes 
derived from iPS cells. If this research 
is deemed to be important and desir-
able, regulators will have to address the 
current limitations imposed in different 
jurisdictions and assess whether they 
meet the needs and expectations of 
their publics.
Clinical Translation
A major hope associated with iPS cell 
technology is that it will facilitate per-
sonalized cell therapies for treating 
human disease. However, the issues 
associated with prospective clinical 
use of these cells are complex. The 
following discussion is not intended to 
be comprehensive but merely to raise 
key issues that need to be considered. 
Transplantation of iPS cells, or their 
derivatives, into humans during clinical 
application of the technology raises at 
least two significant safety concerns. 
The first centers on the in vivo proper-
ties of immortal cell types, and the sec-
ond on the fact that potential therapies 
may include genetically manipulated ecember 11, 2009 ©2009 Elsevier Inc. 1035
cell types. Given this, the regulatory 
hurdles are likely to be high. The rela-
tive novelty of this technology may also 
require new methods of quality assess-
ment and evaluation, especially as iPS 
cell production is scaled up to meet the 
therapeutic quantities needed.
Defining cell types is likely to prove 
challenging and regulators will need to 
consider a variety of questions. These 
include defining the characteristics of 
an iPS cell and addressing differences 
in cell type, derivation process, and dif-
ferentiation potential. How will genetic 
alterations be defined and character-
ized? Variations in iPS cell processing 
and manufacture may make it challeng-
ing to assess the safety and potency of 
iPS cell products for clinical use. For 
example, the genomic stability of iPS 
cells during culture is not yet well estab-
lished, and assays of the genetic and 
epigenetic status of iPS cells are still in 
flux. It is imperative that regulators and 
scientists work together to develop uni-
form reference standards for acceptable 
changes in iPS cells during culture to 
ensure the quality and safety of iPS cell 
products and to facilitate comparisons 
across many different cell lines.
One important question is whether 
iPS cells will be governed by the same 
regulations that apply to other cell-
based products, or whether they will be 
treated as exceptional, thus warranting 
a unique regulatory pathway. Given the 
particular characteristics of iPS cells 
(and of their derivation processes), tradi-
tional cell-based product review is likely 
to be relatively complicated and lengthy. 
Conversely, if iPS cells are deemed to be 
exceptional and distinct, new rules and 
procedures could be developed to gov-
ern their use. For example, a new stem 
cell research oversight committee with 
specialist skills could facilitate smoother 
and faster clinical translation. However, 
such a view of exceptionalism could 
also trigger a level of increased scrutiny. 
Many jurisdictions have yet to address 
this issue, leaving iPS cells unregulated 
or in limbo.
Another important issue is whether 
every new iPS cell line will need to be 
considered as an individual product for 
evaluation or whether a process approval 
approach will suffice. Given that the cells 
are heavily manipulated in culture, that 1036 Cell 139, December 11, 2009 ©2009 Eeach cell type has its own in vitro and in 
vivo homeostatic behavior, and that the 
same lines behave differently in different 
hands, it seems unlikely that standard 
approval processes for stem cells will 
be applied. However, the cost implica-
tions associated with individual cell line 
approvals would likely be prohibitive for 
general clinical use, and almost certainly 
for personalized treatments. One solu-
tion might be to allow approval based 
on methods (as in surgical procedures) 
rather than on products. Regulators 
and developers should be able to use 
their experience from past cell therapy 
approvals to inform and speed future iPS 
cell Investigational New Drug Applica-
tions (in the US), and similar processes 
in other regions.
One practical impediment to the effi-
cient development of shared standards 
results from commercial pressures. 
It is instructive to examine the initial 
approval earlier this year by the US 
Food and Drug Administration (FDA) of 
a clinical trial by Geron of hESC-derived 
oligodendrocyte progenitor cells in 
spinal cord injury patients, which was 
subsequently placed on hold pending 
further data. The basis upon which the 
company was able to satisfy the FDA 
regarding safety, efficacy, and manu-
facturing remains confidential. Accord-
ingly, new applications cannot learn 
from the Geron precedent. Such regula-
tory structure challenges are not unique 
to the FDA and are faced by compara-
ble agencies in many regions. Potential 
policy solutions to these challenges, 
such as requiring companies entering 
or already in Phase 0 or 1 clinical trials 
to make their key safety data available 
for researchers and oversight commit-
tees, must be considered.
These challenges are amplified by 
international variations in regulatory 
regimes. In many countries, the regula-
tory pathway for the clinical use of iPS 
cells is very complex, and in others, 
the scope and nature of this area of 
regulation is unsettled. As the iPS cell 
field develops, there may be consortia 
approaches to biobanking iPS cell lines, 
where a number of smaller biobanks 
merge their information to facilitate sub-
sequent inter-jurisdictional sharing of 
materials. Although potentially beneficial, 
these activities will inevitably encounter lsevier Inc.ethical, regulatory, and institutional dis-
continuities based on jurisdictional dif-
ferences in policies and regulation.
Conclusions
The relative ease of access to iPS cell 
technology presents a new opportunity 
for researchers to become involved in 
the stem cell arena. In many cases, these 
new entrants have not played a role in the 
past debates surrounding hESC research 
and they may bring fresh perspectives 
to otherwise well-trodden discussions. 
Accordingly, it is an ideal time to engage 
in thoughtful debate regarding the issues 
raised by iPS cells, with a view to produc-
ing clear and consistent policies in this 
realm, and perhaps contributing to the 
broader stem cell research discourse. 
This ethical examination should also con-
sider other key concerns not addressed 
here, such as social justice, therapeutic 
misconceptions regarding prospective 
treatments, potential harm to vulnerable 
populations, fair access to useful treat-
ments, and the premature use and imple-
mentation of therapies for financial gain. 
The impact of the increasing pressure 
to move toward clinical translation and 
commercialization should also be consid-
ered. The mistakes associated with gene 
therapy, including the push to produce 
clinical applications and the associated 
clinical trial debacle (Wilson, 2009), and 
the type of initial hype and alarm that sur-
rounded the first uses of SCNT, must be 
avoided. Nonetheless, approaching iPS 
cell developments in a measured manner 
does not preclude embracing the pro-
found scientific and therapeutic potential 
of this exciting area.
Despite the significant commonalities 
with hESC research, iPS cell technology 
is distinct in a number of ways and shares 
elements with other domains of biomedi-
cal research such as genetics and gene 
transfer. The analysis that accompanied 
these areas can inform issues associ-
ated with iPS cell technology. That said, 
the degree to which iPS cells and the 
issues they raise are sufficiently unique 
from other forms of research, thus war-
ranting exceptional treatment, remains 
an open question. A focused consider-
ation is needed to determine, in a clear 
and principled manner, where iPS cell 
technology fits in the broader research 
policy framework.
The profound promise of iPS cell 
research cannot be responsibly sepa-
rated from attendant ethical, legal, 
and social issues. Given the potential 
risks involved and the global nature 
of this fast-moving field, thoughtful 
consideration of the relevant issues 
and responsible action on the part of 
scientists, policy makers, and stake-
holders alike is necessary. It will be 
important to encourage comprehen-
sive education among researchers 
(especially new entrants to the field of 
stem cell research) regarding emerging 
guidelines and principles in order to 
encourage careful adherence to these 
policies. These steps are necessary 
to safeguard public trust and facili-
tate responsible pursuit of the exciting 
possibilities associated with iPS cell 
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